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Neurodegenerative diseases are amongst the most costly and
devastating diseases, both to patients as well as to their fam-
ilies. This year will mark the 100th anniversary of the ﬁrst
case description of what we now call Alzheimer’s disease, the
most common neurodegenerative disease. This special time
provides a unique opportunity for us to reﬂect on how much
we have learned and yet to also appreciate how much more
is left to do to solve this enormous health and social prob-
lem. Indeed, there has been an exponential increase in our
knowledge of disease mechanisms especially during the past
decade: the old doctrine was rejected while new ones arose
from its debris. This is a fascinating and, we believe, criti-
cal period for novel ﬁndings and new ideas to quickly and
globally change our understanding of Alzheimer’s disease
and other neurodegenerative diseases. At this historical time,
in this issue of the Journal of Biomedicine and Biotechnol-
ogy, we have been fortunate to gather some of the foremost
thinkers in the ﬁeld to discuss up-to-date information con-
cerning new developments in this exciting area of research as
well as their therapeutic implications. This area of research
has attracted some of the most innovative research groups in
the ﬁeld and, as Editors, we are truly privileged that many of
these investigators have contributed to this issue. We express
our sincerest gratitude to the contributing authors as well as
to the vision of the Editor-in-Chief, Dr Abdelali Haoudi, for
the opportunity provided by the Journal of Biomedicine and
Biotechnology.
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Alzheimer’s disease is a major public health problem because it has
a huge impact on individuals, families, and society and it has at-
tracted increasing public attention as the population ages, which
highlights the urgency to understand and treat this disease eﬀec-
tively. This group demonstrated that both oxidative stress and cell
cycle-related abnormalities are among the earliest contributors to
thedisease.Themajorhypothesisbeingpursuedisthatwhileeither
oxidative stress or abnormalities in mitotic signaling can indepen-
dently serve as initiators, both processes are necessary to propagate
disease pathogenesis and progression.
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